Cantor Fitzgerald reiterated their overweight rating on shares of Aptose Biosciences (TSE:APS – Get Rating) (NASDAQ:APTO) in a research report report published on Wednesday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Aptose Biosciences’ FY2022 earnings at ($0.60) EPS and FY2023 earnings at ($0.56) EPS.
Separately, Jonestrading restated a buy rating and set a C$5.00 price target on shares of Aptose Biosciences in a report on Friday, June 3rd.
Aptose Biosciences Stock Performance
Aptose Biosciences stock opened at C$0.80 on Wednesday. Aptose Biosciences has a 12-month low of C$0.79 and a 12-month high of C$3.53. The company has a quick ratio of 6.70, a current ratio of 6.89 and a debt-to-equity ratio of 0.72. The business’s 50-day moving average price is C$1.01 and its two-hundred day moving average price is C$1.24. The stock has a market cap of C$73.84 million and a PE ratio of -0.91.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.